首页 中华结核和呼吸杂志 2019年42卷2期 亚胺吩嗪类药物抗结核作用研究进展
中华结核和呼吸杂志
期刊首页
过刊列表
高级检索
稿件发表
• 综述 •
ENGLISH ABSTRACT
亚胺吩嗪类药物抗结核作用研究进展
张叶 
陆宇 
作者及单位信息
·
DOI： 10.3760/cma.j.issn.1001-0939.2019.02.008
Research progress on the anti⁃tuberculosis effect of riminophenazines
Zhang Ye
Lu Yu
Authors Info & Affiliations
Zhang Ye
Lu Yu
·
DOI： 10.3760/cma.j.issn.1001-0939.2019.02.008
779
59
0
1
1
0
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
亚胺吩嗪类药物同时具有抗分枝杆菌和抗炎的双重活性，但早年由于其疗效仅在麻风病治疗中得到证实，并未广泛用于结核病临床治疗。近年来该类药物中氯法齐明的抗MTB活性已得到证实，并被世界卫生组织推荐为耐多药结核病的核心二线治疗药物。氯法齐明的结构改造物也在不断的被合成和筛选，其中吡法齐明活性更强而不良反应更弱，是我国首个拥有自主知识产权的抗MTB新药。
引用本文
张叶,陆宇. 亚胺吩嗪类药物抗结核作用研究进展[J]. 中华结核和呼吸杂志,2019,42(2)：118-121.
DOI:10.3760/cma.j.issn.1001-0939.2019.02.008PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
0分
[累计0个]
向我们报错
参考文献
[1]
Barry VC , Belton JG , Conalty ML ,et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity[J]. Nature, 1957,179(4568):1013-1015. DOI:
10.1038/1791013a0
.
[2]
Barry VC , Conalty ML . The Antimycobacterial Activity of B 663[J]. Lepr Rev, 1965,36(1):3-7. DOI:
10.5935/0305-7518.19650002
.
[3]
Swanson RV , Adamson J , Moodley C ,et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis[J]. Antimicrob Agents Chemother, 2015,59(6):3042-3051. DOI:
10.1128/AAC.00260-15
.
[4]
Banerjee DK , Ellard GA , Gammon PT ,et al. Some observations on the pharmacology of clofazimine (B663)[J]. Am J Trop Med Hyg, 1974,23(6):1110-1115. DOI:
10.4269/ajtmh.1974.23.1110
.
[5]
Mothiba MT , Anderson R , Fourie B ,et al. Effects of clofazimine on planktonic and biofilm growth of Mycobacterium tuberculosis and Mycobacterium smegmatis[J]. J Glob Antimicrob Resist, 2015,3(1):13-18. DOI:
10.1016/j.jgar.2014.12.001
.
[6]
Irwin SM , Gruppo V , Brooks E ,et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas[J]. Antimicrob Agents Chemother, 2014,58(7):4026-4034. DOI:
10.1128/AAC.02565-14
.
[7]
Ammerman NC , Swanson RV , Tapley A ,et al. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo[J]. J Antimicrob Chemother, 2016,72(2):455-461. DOI:
10.1093/jac/dkw417
.
[8]
Zhang S , Shi W , Feng J ,et al. Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro[J]. Emerg Microbes Infect, 2017,6(4):e28. DOI:
10.1038/emi.2017.24
.
[9]
陆宇. 氯法齐明与其他抗结核药物联用对结核分枝杆菌的作用[J]. 中华结核和呼吸杂志， 2010，33(9):675-678. DOI:
10.3760/cma.j.issn.1001-0939.2010.09.010
.
[10]
De Logu A , Onnis V , Saddi B ,et al. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2002,49(2):275-282.
[11]
Zhao W , Zheng M , Wang B ,et al. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo[J]. Int J Infect Dis, 2016,52:23-28. DOI:
10.1016/j.ijid.2016.08.027
.
[12]
Sangana R , Gu H , Chun DY ,et al. Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches[J]. Drug Metab Dispos, 2018,46(1):26-32. DOI:
10.1124/dmd.117.077834
.
[13]
Lu Y , Zheng M , Wang B ,et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation[J]. Antimicrob Agents Chemother, 2011,55(11):5185-5193. DOI:
10.1128/AAC.00699-11
.
[14]
Zhang D , Lu Y , Liu K ,et al. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis[J]. J Med Chem, 2012,55(19):8409-8417. DOI:
10.1021/jm300828h
.
[15]
Matlola NM , Steel HC , Anderson R . Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine[J]. J Antimicrob Chemother, 2001,47(2):199-202.
[16]
Zhang D , Liu Y , Zhang C ,et al. Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents[J]. Molecules, 2014,19(4):4380-4394. DOI:
10.3390/molecules19044380
.
[17]
李聃，盛莉，赵曼曼，等. 新型抗结核化合物TBI-166在比格犬体内的生物利用度[J]. 国际药学研究杂志， 2015，42(2):194-198+205. DOI:
10.13220/j.cnki.jipr.2015.02.013
.
[18]
Yano T , Kassovska-Bratinova S , Teh JS ,et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species[J]. J Biol Chem, 2011,286(12):10276-10287. DOI:
10.1074/jbc.M110.200501
.
[19]
Cholo MC , Steel HC , Fourie PB ,et al. Clofazimine: current status and future prospects[J]. J Antimicrob Chemother, 2012,67(2):290-298. DOI:
10.1093/jac/dkr444
.
[20]
Cholo MC , Boshoff HI , Steel HC ,et al. Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2006,57(1):79-84. DOI:
10.1093/jac/dki409
.
[21]
Fukutomi Y , Maeda Y , Makino M . Apoptosis-inducing activity of clofazimine in macrophages[J]. Antimicrob Agents Chemother, 2011,55(9):4000-4005. DOI:
10.1128/AAC.00434-11
.
[22]
Hartkoorn RC , Uplekar S , Cole ST . Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2014,58(5):2979-2981. DOI:
10.1128/AAC.00037-14
.
[23]
Zhang S , Chen J , Cui P ,et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2015,70(9):2507-2510. DOI:
10.1093/jac/dkv150
.
[24]
Xu J , Wang B , Hu M ,et al. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis[J]. Antimicrob Agents Chemother, 2017,61(6):
10.1128/aac.00239-17
. DOI:.
[25]
Almeida D , Ioerger T , Tyagi S ,et al. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2016,60(8):4590-4599. DOI:
10.1128/AAC.00753-16
.
[26]
左小淑. 吩嗪类化合物作用机制的初步研究[D]. 北京市结核病胸部肿瘤研究所, 2015.
[27]
Ahmad Khan F , Salim MAH , du Cros P ,et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses[J]. Eur Respir J, 2017,50(1).
10.1183/13993003.00061-2017
. DOI:.
[28]
World Health Organization. Global tuberculosis report 2016[M]. Geneva:World Health Organization, 2016.
[29]
Tang S , Yao L , Hao X ,et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China[J]. Clin Infect Dis, 2015,60(9):1361-1367. DOI:
10.1093/cid/civ027
.
[30]
Piubello A , Harouna SH , Souleymane MB ,et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses[J]. Int J Tuberc Lung Dis, 2014,18(10):1188-1194. DOI:
10.5588/ijtld.13.0075
.
[31]
Dey T , Brigden G , Cox H ,et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2013,68(2):284-293. DOI:
10.1093/jac/dks389
.
[32]
Gopal M , Padayatchi N , Metcalfe JZ ,et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis[J]. Int J Tuberc Lung Dis, 2013,17(8):1001-1007. DOI:
10.5588/ijtld.12.0144
.
[33]
Padayatchi N , Gopal M , Naidoo R ,et al. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study[J]. J Antimicrob Chemother, 2014,69(11):3103-3107. DOI:
10.1093/jac/dku235
.
[34]
Tyagi S , Ammerman NC , Li SY ,et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis[J]. Proc Natl Acad Sci U S A, 2015,112(3):869-874. DOI:
10.1073/pnas.1416951112
.
[35]
Somoskovi A , Bruderer V , Homke R ,et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment[J]. Eur Respir J, 201545(2):554-557. DOI:
10.1183/09031936.00142914
.
[36]
Ismail NA , Omar SV , Joseph L ,et al. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: a Retrospective Cohort Study[J]. EBioMedicine, 2018,28:136-142. DOI:
10.1016/j.ebiom.2018.01.005
.
[37]
Olaru ID , Von Groote-Bidlingmaier F , Heyckendorf J ,et al. Novel drugs against tuberculosis: a clinician′s perspective[J]. Eur Respir J, 2015,45(4):1119-1131. DOI:
10.1183/09031936.00162314
.
[38]
Ammerman NC , Swanson RV , Bautista EM ,et al. Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis[J]. Antimicrob Agents Chemother, 2018,62(7).
10.1128/AAC.00636-18
. DOI:.
[39]
Xu HB , Jiang RH , Xiao HP . Clofazimine in the treatment of multidrug-resistant tuberculosis[J]. Clin Microbiol Infect, 2012,18(11):1104-1110. DOI:
10.1111/j.1469-0691.2011.03716.x
.
[40]
Arbiser JL , Moschella SL . Clofazimine: a review of its medical uses and mechanisms of action[J]. J Am Acad Dermatol, 1995,32(2Pt 1):241-247.
[41]
Barteselli A , Casagrande M , Basilico N ,et al. Clofazimine analogs with antileishmanial and antiplasmodial activity[J]. Bioorg Med Chem, 2015,23(1):55-65. DOI:
10.1016/j.bmc.2014.11.028
.
[42]
Durusu IZ , Husnugil HH , Atas H ,et al. Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line[J]. Leuk Res, 2017,55(2017):33-40. DOI:
10.1016/j.leukres.2017.01.019
.
备注信息
A
陆宇，Email：
mocdef.aabnis6784uyul
B
所有作者均声明没有利益冲突
C
"重大新药创制"科技重大专项 (2015ZX09102007-015)
北京市医院管理局"登峰"人才培养计划 (DFL20151501)
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
糖皮质激素类药物临床应用指导原则(2023版)
中华医学会内分泌学分会 等 中华内分泌代谢杂志 2023,39(04)
抗结核新药吡法齐明组合用药的体外及小鼠体内抗结核活性研究
刘海婷 等 中华结核和呼吸杂志 2022,45(06)
利奈唑胺抗结核治疗专家共识（2022年版）
中华医学会结核病学分会 中华结核和呼吸杂志 2022,45(10)
抗肽酰基精氨酸脱亚胺酶4抗体在类风湿关节炎中的作用研究进展
姜钒 等 中华医学杂志 2021,101(22)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
